Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Meditera Tibbi Malzeme Sanayi ve Ticaret AS TRY 20.55, price TRY 18.50, upside +11.1%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range 7.53 TRY – 52.24 TRY · fair‑value band 15.33 TRY – 25.78 TRY · the 18.50 TRY price screens below the 20.55 TRY fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Meditera Tibbi Malzeme Sanayi ve Ticaret AS in your weekly email
Every Wednesday you see whether Meditera Tibbi Malzeme Sanayi ve Ticaret AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi manufactures and sells medical devices in Turkey.
Show more
Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi manufactures and sells medical devices in Turkey. The company offers two-way and single-line Infusion Systems; Chemotherapy Preparation and Administration Systems, such as medoconco automated drug preparation, diana semi-automatic drug dispensing, and ICU medical chemotherapy drug delivery systems; and respiratory systems products, including respiratory circuits, respiratory filters, catheter mounts, gas sampling lines, accessories, masks, and connectors. It also provides hospital products, such as barrier cream, surgical hand brushes for skin disinfection, hand and skin antiseptics, and skin and mucosa antiseptics. In addition, the company provides surgical solutions, including absorbable and absorbable sutures, and hemostatic products; installation, operation, and design of oncology drug preparation and delivery systems; production, sales, and technical service of infusion pumps and sets; and manufacturing of biocidal products. It also exports its products to 80 countries under its Altech brand name. Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi was founded in 1983 and is headquartered in Izmir, Turkey.
Stock analysis
Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) currently trades at 18.50 TRY, while our model-based Fair Value estimate is 20.55 TRY, implying the stock looks roughly 10.0% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 67.99 TRY per share, and 11 of the 15 models we run sit above the 18.50 TRY price.
Bear case: the Dividend Discount group reads lowest at 6.11 TRY, and 4 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: 15.33 TRY (bear) to 25.78 TRY (bull), the price of 18.50 TRY sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Meditera Tibbi Malzeme Sanayi ve Ticaret AS reported revenue of 2.9B TRY in FY2025 versus 376M TRY in FY2021, a compound +66.3%/yr. Reported net income was −9.3M TRY in FY2025.
Key figures
Market cap 2.2B TRY (≈ $44.8M) · P/E ratio 61.7 · P/S ratio 0.67 · EPS (TTM) 0.3000 TRY · Dividend yield 2.2% · Net margin −0.3% · Return on equity 1.3% · Return on assets (EBIT) 11.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 43% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 11%, MEDTR screens cheaper than that median.
Fair Value models
Bear 15.33 TRYFair Value 20.55 TRYBull 25.78 TRY
Price 18.50 TRY · Upside +11.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.2285 TRY per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+52.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.4%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.4% (2019) → 4.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Turkey: IMF forecast 19.3% a year to 2030, 28.5% from 2016 to 2025) that is about −17.7% a year for the price.
Compare Meditera Tibbi Malzeme Sanayi ve Ticaret AS with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 336 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside+11.1% · Above median
Profitability
Return on equity (TTM)1.3% · Below median
Return on assets1.0% · Below median
Net margin (TTM)1.4% · Below median
Operating margin (TTM)5.7% · Below median
Growth and dividend
Revenue growth−18.3% · Bottom 25%
Dividend yield (TTM)2.2% · Above median
Balance sheet
Debt / equity0.00× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Meditera Tibbi Malzeme Sanayi ve Ticaret AS Fair Value". https://www.fairvalue-calculator.com/stock/MEDTR
Frequently asked questions
Is Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of 20.55 TRY versus a price of 18.50 TRY, about +11% upside (undervalued).
What is the fair value of MEDTR?
Our model-based fair value for Meditera Tibbi Malzeme Sanayi ve Ticaret AS is 20.55 TRY (as of Oct 4, 2026), built from audited fundamentals. The current price: 18.50 TRY.
What is the quality score of MEDTR?
Meditera Tibbi Malzeme Sanayi ve Ticaret AS has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
Our model-based price target is the fair value of 20.55 TRY (as of Oct 4, 2026) from 15 valuation models. Cautious scenario 15.33 TRY, optimistic scenario 25.78 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the Meditera Tibbi Malzeme Sanayi ve Ticaret AS stock forecast for 2026?
Our models put fair value at 20.55 TRY, about +11% upside versus a price of 18.50 TRY (undervalued). Cautious scenario 15.33 TRY, optimistic scenario 25.78 TRY. The calculation is refreshed regularly with new filings.
What is the revenue of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
Meditera Tibbi Malzeme Sanayi ve Ticaret AS reported trailing-twelve-month revenue of about 2.6B TRY (latest available figure, as of Oct 4, 2026).
Does Meditera Tibbi Malzeme Sanayi ve Ticaret AS pay a dividend?
Meditera Tibbi Malzeme Sanayi ve Ticaret AS currently shows a dividend yield of about 2.19% relative to its recent price (as of Oct 4, 2026).
What growth is priced into Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
For today's price to be fair in a discounted-cash-flow model, Meditera Tibbi Malzeme Sanayi ve Ticaret AS would have to grow free cash flow by -1.8 % per year for five years (discount rate 12.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +51.6 % per year. As of Oct 4, 2026.
What discount rate (WACC) does the fair value of MEDTR use?
Our models discount Meditera Tibbi Malzeme Sanayi ve Ticaret AS at 12.7 %: a base by market capitalisation (nano), damped by beta 0.39, country premium for Turkey. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Meditera Tibbi Malzeme Sanayi ve Ticaret AS that is -1.8 % per year a year over ten years, using the same discount rate (12.7 %) and the same formula as our fair value.
How much growth has Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) delivered so far?
Over the past 5 years revenue at Meditera Tibbi Malzeme Sanayi ve Ticaret AS grew +51.6 % a year. The price currently implies -1.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Meditera Tibbi Malzeme Sanayi ve Ticaret AS (-1.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
The free-cash-flow yield on the price is 11.07 %: that much free cash flow Meditera Tibbi Malzeme Sanayi ve Ticaret AS produces per unit of market value. When it exceeds the discount rate of our models (12.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Meditera Tibbi Malzeme Sanayi ve Ticaret AS it is 20.55 TRY per share (as of Oct 4, 2026), against a price of 18.50 TRY. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Meditera Tibbi Malzeme Sanayi ve Ticaret AS stock overvalued or undervalued in 2026?
As of Oct 4, 2026, MEDTR trades below its calculated fair value: price 18.50 TRY, fair value 20.55 TRY, a gap of about +11% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDTR?
No. The price is what the market pays today (18.50 TRY); the fair value is what the company's own numbers justify (20.55 TRY). For Meditera Tibbi Malzeme Sanayi ve Ticaret AS the two are 2.05 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is Meditera Tibbi Malzeme Sanayi ve Ticaret AS worth?
The market values Meditera Tibbi Malzeme Sanayi ve Ticaret AS at about 2.2B TRY (market capitalisation, as of Oct 4, 2026). Per share that is 18.50 TRY; our models calculate a fair value of 20.55 TRY per share.
What do the bullish and bearish scenarios say about MEDTR?
Our models span a range for Meditera Tibbi Malzeme Sanayi ve Ticaret AS: cautious scenario 15.33 TRY, base 20.55 TRY, optimistic 25.78 TRY per share (as of Oct 4, 2026, price 18.50 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDTR?
Meditera Tibbi Malzeme Sanayi ve Ticaret AS trades at a price-to-earnings ratio of 61.7 (as of Oct 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 20.55 TRY is built from several models across several years. Other multiples: P/B 0.8, P/S 0.9, EV/EBITDA 8.5.
How solid is the balance sheet of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
Balance-sheet figures for Meditera Tibbi Malzeme Sanayi ve Ticaret AS (as of Oct 4, 2026): return on equity 1.3%, debt of 0.00 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is MEDTR from its 52-week high?
Meditera Tibbi Malzeme Sanayi ve Ticaret AS trades at 18.50 TRY, about 43% below its 52-week high of 32.56 TRY and 3% above the low of 17.95 TRY (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 20.55 TRY is for.
Which stocks are comparable to Meditera Tibbi Malzeme Sanayi ve Ticaret AS?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Meditera Tibbi Malzeme Sanayi ve Ticaret AS stock attractive at the current price?
The data as of Oct 4, 2026: price 18.50 TRY, calculated fair value 20.55 TRY (+11%), Quality Score 44/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDTR calculated?
We run Meditera Tibbi Malzeme Sanayi ve Ticaret AS through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 20.55 TRY, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Meditera Tibbi Malzeme Sanayi ve Ticaret AS currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
The closing price on Oct 2, 2026 was 18.50 TRY. Our model-based fair value is 20.55 TRY, about +11% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Meditera Tibbi Malzeme Sanayi ve Ticaret AS right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Meditera Tibbi Malzeme Sanayi ve Ticaret AS
How large is the market capitalisation of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
The market capitalisation of Meditera Tibbi Malzeme Sanayi ve Ticaret AS is 2.2B TRY (≈ $44.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
The price-to-sales ratio of Meditera Tibbi Malzeme Sanayi ve Ticaret AS is 0.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
Earnings per share at Meditera Tibbi Malzeme Sanayi ve Ticaret AS are 0.3000 TRY (price ÷ EPS = P/E 61.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
The dividend yield of Meditera Tibbi Malzeme Sanayi ve Ticaret AS is 2.2% (payout 135%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
The net margin of Meditera Tibbi Malzeme Sanayi ve Ticaret AS is −0.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
The return on equity (ROE) of Meditera Tibbi Malzeme Sanayi ve Ticaret AS is 1.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
On an EBIT basis the return on assets of Meditera Tibbi Malzeme Sanayi ve Ticaret AS is 11.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
The operating margin of Meditera Tibbi Malzeme Sanayi ve Ticaret AS is 5.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
Revenue at Meditera Tibbi Malzeme Sanayi ve Ticaret AS is growing −18.3% versus a year earlier (3y avg +52.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR)?
Earnings per share at Meditera Tibbi Malzeme Sanayi ve Ticaret AS are growing +323% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) carry?
The net debt of Meditera Tibbi Malzeme Sanayi ve Ticaret AS is 32.7M TRY (fiscal year 2019, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Meditera Tibbi Malzeme Sanayi ve Ticaret AS in the live analysis
One click puts Meditera Tibbi Malzeme Sanayi ve Ticaret AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
